RESONANCE: Protocol for a Nationwide Cohort Study of Chronic Liver Diseases Using the French National Health Data System.
8 affiliations
- 1Université Grenoble Alpes, Institute for Advanced Biosciences, Research Center UGA Inserm U 1209 - CNRS UMR 5309, Team Cell Dynamics, Metabolism & Cancer (DIMAC), Grenoble, Île-de-France, France.
- 2Université Paris Saclay, Centre Hépato-Biliaire, Hôpital Paul-Brousse, Inserm UMR 1193, Villejuif, France.
- 3Université Grenoble Alpes, Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, La Tronche, Grenoble, France.
- 4Pharmacovigilance and Pharmacoepidemiology, CHU Rennes, Rennes, France.
- 5Université Rennes, CHU Rennes, Inserm, EHESP, Irset, UMR_S 1085, Rennes, France.
- 6Université Grenoble Alpes, Pôle Santé Publique, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
- 7Université Grenoble Alpes, TIMC-IMAG, UMR 5525, CNRS, Equipe ThEMAS, Grenoble, France.
- 8Université Grenoble Alpes, HP2 Laboratory, Inserm U1300, Grenoble, France.
Abstract
Background
Chronic liver diseases (CLDs) are frequent in Europe, including in France, and are mainly driven by alcohol, metabolic dysfunction (diabetes and obesity), and viral hepatitis. Although risk factors are well established and easy to identify, CLDs are frequently diagnosed at an advanced stage, translating into poor prognosis. Descriptive data on CLD burden in France remain scarce, and health trajectories of these patients are uncharted. However, such data are crucial to guide clinical practice, to determine the target population for personalized public health policies, and to develop innovative strategies to reduce inequities in access to health care and ultimately improve survival.Objective
The aim of the French RESONANCE cohort is to provide a detailed description of CLD burden in France and study health trajectories.Methods
The RESONANCE cohort was derived from the French National Health Data System (Système National des Données de Santé [SNDS]). Patients with at least one CLD-specific ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (including primary liver cancer [PLC] and rare diseases), or related procedure, biology, or drug and/or a cause of death related to one of these ICD-10 codes, were targeted from the 2% representative SNDS sample (ESND [Échantillon du Système National des Données], Simplified Sample of the French National Health Data System). Demographic characteristics, risk factors, comorbidities, etiologies, social environment and health care accessibility, as well as severity of the liver disease at first identification and medical management, were assessed. This paper describes the procedures used to build the cohort, outlines main variables, and defines the research objectives.Results
Overall, 26,663 incident and prevalent CLD cases identified between 2015 and 2021 were included in the RESONANCE cohort. Men accounted for 58.1% (15,490) of the cohort, and the mean age was 59.9 (SD 17.4) years. The cohort covers a broad spectrum of etiologies, including alcohol-related liver disease (7580/26,663, 28.4%), metabolic-associated liver disease (6030/26,663, 24.8%), viral hepatitis (3450/26,663, 12.9%), and rare liver diseases (839/26,663, 3.1%). A total of 43% (11,461/26,663) of the patients lived in a socially deprived environment (according to the 4th and 5th quintiles of the French Deprivation Index).Conclusions
This paper will enable a detailed, real-world analysis of epidemiology, care trajectories, and outcomes of CLDs across France. With a particular focus on gender and socioeconomic disparities, it offers a unique opportunity to identify vulnerable populations and inform proportionate universalism strategies in prevention and care.International registered report identifier (irrid)
DERR1-10.2196/89577.
Related
- National trends in chronic kidney disease prevalence by sleep duration in South Korea, 2007 to 2022 : A nationwide cross-sectional study
- Prevalence and mortality of chronic extracellular matrix dysregulated diseases: a nationwide register-based study
- Association Between Periodontal Status and Undiagnosed Diabetes in Adults Without Diagnosed Chronic Diseases: The Korea National Health and Nutrition Examination Survey 2013–2015
- Interpreting the Early Cancer Peak in Immune-Mediated Inflammatory Diseases. Comment on Giordani et al. Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study. Cancers 2026, 18, 1027
- Nationwide implementation of digital non-communicable diseases screening in Indonesia’s primary care system
BibTeX
@article{baron2026resonance,
title = {{RESONANCE: Protocol for a Nationwide Cohort Study of Chronic Liver Diseases Using the French National Health Data System.}},
author = {Aurore Baron and Laure Tron and Frédéric Balusson and Vaele Zannou and Victoria Mignot and Anne Ego and Anna Borowick and Thomas Decaens and Emmanuel Oger and Sébastien Bailly and Charlotte Costentin},
journal = {JMIR research protocols},
year = {2026},
month = oct,
doi = {10.2196/89577},
url = {https://europepmc.org/article/MED/42832782},
note = {CC BY},
}
RIS
TY - JOUR
TI - RESONANCE: Protocol for a Nationwide Cohort Study of Chronic Liver Diseases Using the French National Health Data System.
AU - Aurore Baron
AU - Laure Tron
AU - Frédéric Balusson
AU - Vaele Zannou
AU - Victoria Mignot
AU - Anne Ego
AU - Anna Borowick
AU - Thomas Decaens
AU - Emmanuel Oger
AU - Sébastien Bailly
AU - Charlotte Costentin
PY - 2026
DA - 2026/10/05
JO - JMIR research protocols
DO - 10.2196/89577
UR - https://europepmc.org/article/MED/42832782
AB - Background Chronic liver diseases (CLDs) are frequent in Europe, including in France, and are mainly driven by alcohol, metabolic dysfunction (diabetes and obesity), and viral hepatitis. Although risk factors are well established and easy to identify, CLDs are frequently diagnosed at an advanced stage, translating into poor prognosis. Descriptive data on CLD burden in France remain scarce, and health trajectories of these patients are uncharted. However, such data are crucial to guide clinical practice, to determine the target population for personalized public health policies, and to develop innovative strategies to reduce inequities in access to health care and ultimately improve survival.Objective The aim of the French RESONANCE cohort is to provide a detailed description of CLD burden in France and study health trajectories.Methods The RESONANCE cohort was derived from the French National Health Data System (Système National des Données de Santé [SNDS]). Patients with at least one CLD-specific ICD-10 (International Statistical Classification of Diseases, Tenth Revision) code (including primary liver cancer [PLC] and rare diseases), or related procedure, biology, or drug and/or a cause of death related to one of these ICD-10 codes, were targeted from the 2% representative SNDS sample (ESND [Échantillon du Système National des Données], Simplified Sample of the French National Health Data System). Demographic characteristics, risk factors, comorbidities, etiologies, social environment and health care accessibility, as well as severity of the liver disease at first identification and medical management, were assessed. This paper describes the procedures used to build the cohort, outlines main variables, and defines the research objectives.Results Overall, 26,663 incident and prevalent CLD cases identified between 2015 and 2021 were included in the RESONANCE cohort. Men accounted for 58.1% (15,490) of the cohort, and the mean age was 59.9 (SD 17.4) years. The cohort covers a broad spectrum of etiologies, including alcohol-related liver disease (7580/26,663, 28.4%), metabolic-associated liver disease (6030/26,663, 24.8%), viral hepatitis (3450/26,663, 12.9%), and rare liver diseases (839/26,663, 3.1%). A total of 43% (11,461/26,663) of the patients lived in a socially deprived environment (according to the 4th and 5th quintiles of the French Deprivation Index).Conclusions This paper will enable a detailed, real-world analysis of epidemiology, care trajectories, and outcomes of CLDs across France. With a particular focus on gender and socioeconomic disparities, it offers a unique opportunity to identify vulnerable populations and inform proportionate universalism strategies in prevention and care.International registered report identifier (irrid) DERR1-10.2196/89577.
SN - 1929-0748
ER -